CLDI

Calidi Biotherapeutics, Inc. (CLDI) Economic Moat Analysis (2026)

Invetso Score: 2.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

CLDI does not show evidence of durable brand, patent, or regulatory intangible assets that translate into pricing power versus peers, so customer willingness to pay appears weak.

The provided profitability metrics are negative, which suggests any intangible advantage is not yet strong enough to support superior margins relative to peers.

No disclosed long-run margin or return history was provided, limiting evidence that intangible assets are compounding into durable competitive differentiation.

Switching Costs

Score:

Negative ROIC and ROCE indicate customers are not yet locked into a high-value workflow that CLDI can monetize through retention versus peers.

The very weak cash conversion cycle does not by itself prove switching costs, and it more likely reflects working-capital strain than customer dependence.

Without evidence of contractual lock-in, embedded software, or mission-critical integration, switching costs appear low relative to stronger peer franchises.

Network Effects

Score:

There is no evidence that CLDI benefits from a self-reinforcing user, data, or marketplace loop that would improve product value as adoption rises.

Unlike peer platforms with clear ecosystem flywheels, CLDI does not appear to have a network structure that materially improves retention or pricing power.

The negative return profile suggests any scale benefits are not yet translating into a visible network-driven moat.

Cost Advantage

Score:

Negative ROIC and ROCE imply CLDI is not currently converting operations into a cost position that is better than peers.

Asset turnover of 0 in the provided data does not support a demonstrated operating efficiency edge, so cost leadership is not evident.

No evidence was provided of proprietary sourcing, manufacturing scale, or structural input advantages that would sustain lower unit costs versus peers.

Efficient Scale

Score:

The available metrics do not show that CLDI operates in a niche where limited market size protects returns from competition.

Negative returns suggest the business is not yet extracting the kind of excess economics that efficient-scale incumbents typically preserve versus peers.

There is no evidence of regulated scarcity, local monopoly characteristics, or capacity constraints that would make scale itself a durable barrier.

Overall Score

Score:

CLDI currently shows little evidence of a durable moat versus peers because the provided metrics point to negative capital returns, weak operating efficiency, and no visible switching-cost, network, or scale-based advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Calidi Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →